| Dr William W Morgan, DDS | |
|
100 Ucla Medical Plz Ste 350, Los Angeles, CA 90095-0001 | |
| (310) 794-5750 | |
| Not Available |
| Full Name | Dr William W Morgan |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 100 Ucla Medical Plz Ste 350, Los Angeles, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003024308 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 23649 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr William W Morgan, DDS 6113 Mary Ellen Ave, Van Nuys, CA 91401-3152 Ph: (818) 781-3433 | Dr William W Morgan, DDS 100 Ucla Medical Plz Ste 350, Los Angeles, CA 90095-0001 Ph: (310) 794-5750 |
News Archive
More problems are being reported in external defibrillators, the life-saving medical devices located in emergency rooms, airports and other public places. These Automated external defibrillators, or AEDs are generally used in patients who have suffered sudden cardiac arrest if used in the first few minutes after their collapse. They deliver electrical energy to the heart to restore its normal rhythm.
Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.
A new study published by the Public Health Agency of Sweden in its Brief Report shows that compared to non-pregnant women, pregnant and postpartum women with COVID-19 have a higher risk of requiring intensive care.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation nCounter Analysis System.
VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary objective for the Phase III part of this study is to determine if Onrigin™ plus LDAC improves overall survival compared with LDAC alone.
› Verified 2 days ago
Dr. Kyung A Lim, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 827 S Berendo St Apt 202, Los Angeles, CA 90005 Phone: 213-219-2530 | |
Sonia Khullar, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 132 S Vermont Avenue, Suite #210, Los Angeles, CA 90004 Phone: 213-389-2625 Fax: 213-389-4736 | |
Dr. Clarice Law Eyre, DMD, MS Dentist Medicare: Not Enrolled in Medicare Practice Location: 100 Ucla Medical Plz Ste 350, Los Angeles, CA 90095 Phone: 310-794-5750 | |
Dr. Arjang Vahidnia, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 7162 Beverly Blvd, #543, Los Angeles, CA 90036 Phone: 310-443-3030 | |
Dr. Adrian Sanchez, Dentist Medicare: Not Enrolled in Medicare Practice Location: 6114 York Blvd, Suite C, Los Angeles, CA 90042 Phone: 323-255-6698 | |
Dr. Bindu Vasudevan Pillai, DDS Dentist Medicare: Medicare Enrolled Practice Location: 5207 Whittier Blvd, Los Angeles, CA 90022 Phone: 323-269-0266 |